Phase II Trial of BIBF1120 (Nintedanib) in Patients With Recurrent or Metastatic Salivary Gland Cancer of the Head and Neck : a Multicentre Phase II Study
Phase of Trial: Phase II
Latest Information Update: 19 Jan 2017
At a glance
- Drugs Nintedanib (Primary)
- Indications Salivary gland cancer
- Focus Therapeutic Use
- 19 Jan 2017 Results published in the Cancer
- 07 Jun 2016 This study has been stopped after an enrolment of 20 patients because no responder was observed at Stage I, as per an abstract presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
- 07 Jun 2016 Status changed from active, no longer recruiting to discontinued, as per an abstract presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.